VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY.
Ramir Luan PerinAderson Omar Mourão Cintra DamiãoCristina FloresJuliano Coelho LudvigDaniela Oliveira MagroEron Fábio MirandaAntonio Carlos da Silva MoraesRodrigo Bremer NonesFábio Vieira TeixeiraMarco Antônio ZerôncioPaulo Gustavo KotzePublished in: Arquivos de gastroenterologia (2019)
Vedolizumab was effective in induction and maintenance of clinical response and remission in CD and UC, with no new safety signs.